CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)
A treatable immune attack on the peripheral nerves
Quick Facts
- Type: Autoimmune peripheral nerve disorder
- Cause: Immune attack on nerve insulation (myelin)
- Course: Chronic, gradual, or relapsing
- Outlook: Often responds to immune treatment
Overview
Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a long-term disorder in which the immune system attacks the myelin, the protective insulating layer around the peripheral nerves. As the myelin is damaged, the nerves can no longer carry signals efficiently, leading to weakness and loss of sensation that usually affect both sides of the body and develop gradually over at least two months.
CIDP is sometimes thought of as a chronic counterpart to Guillain-Barre syndrome, which causes similar nerve damage but comes on rapidly over days to weeks. CIDP instead progresses slowly or in a relapsing pattern. It is one of the more treatable nerve disorders, and early treatment to calm the immune system gives the best chance of preserving and recovering function.
Symptoms
Symptoms typically build up gradually and affect both sides of the body fairly symmetrically.
- Progressive weakness in the arms and legs, often including the muscles closer to the trunk
- Numbness and tingling, usually starting in the feet and hands
- Loss of reflexes
- Difficulty walking, climbing stairs, or rising from a chair
- Trouble with fine movements such as buttoning clothes
- Fatigue and, in some people, an unsteady gait from loss of position sense
Worsening weakness, difficulty walking safely, or any trouble breathing or swallowing should be evaluated promptly.
Causes
CIDP is an autoimmune disorder, meaning the immune system mistakenly attacks the body's own tissue, in this case the myelin of the peripheral nerves. The exact trigger is unknown.
- Immune-mediated demyelination: Immune cells and antibodies damage the myelin sheath, slowing or blocking nerve signals.
- Associated conditions: CIDP can occur on its own or alongside conditions such as diabetes, certain infections, or abnormal blood proteins.
Unlike Guillain-Barre syndrome, CIDP is not usually preceded by a clear infection, and it follows a chronic rather than a sudden course.
Risk Factors
- The cause is unknown and CIDP can affect anyone
- It is somewhat more common in adults and in men
- Coexisting conditions such as diabetes or an abnormal blood protein may be associated
- A personal tendency toward autoimmune disease may contribute
Diagnosis
Diagnosis combines the clinical pattern with tests that show demyelinating nerve damage, while excluding other causes.
- Nerve conduction studies and EMG: The key tests, showing slowed conduction and blocks consistent with demyelination.
- Spinal fluid analysis: Often shows raised protein, supporting an inflammatory cause.
- Blood tests: Used to look for associated conditions and rule out other neuropathies.
- MRI or nerve biopsy: Occasionally used in uncertain cases.
Treatment
CIDP responds to treatments that reduce the immune attack on the nerves, and several effective options exist.
- Corticosteroids: Anti-inflammatory medicines that are a common first-line treatment.
- Intravenous immunoglobulin (IVIG): Modulates the immune system and is frequently effective; a subcutaneous form is also available.
- Plasma exchange: Removes harmful antibodies from the blood and can produce rapid improvement.
- Other immune therapies: Additional immunosuppressants for people who do not respond adequately.
- Rehabilitation: Physical and occupational therapy to maintain strength and function.
Many people improve substantially, though treatment is often needed long term and adjusted over time.
Living With the Condition
- CIDP cannot be prevented because its trigger is unknown
- Early diagnosis and treatment offer the best chance of recovery and preventing lasting nerve damage
- Take immune-modulating treatments as prescribed and attend follow-up
- Use physical therapy to maintain strength, balance, and mobility
- Report any worsening weakness so treatment can be adjusted
When to See a Doctor
See a doctor for gradually worsening weakness or numbness in the arms and legs, especially when it affects both sides and impairs walking or hand use. Seek urgent care if you develop:
- Rapidly progressing weakness
- Difficulty breathing or swallowing
- Inability to walk safely or stand
Early evaluation matters because timely treatment can prevent permanent nerve damage.
Frequently Asked Questions
What is CIDP?
CIDP, or chronic inflammatory demyelinating polyneuropathy, is a long-term autoimmune disorder in which the immune system attacks the myelin insulation around the peripheral nerves. This causes gradual weakness and numbness in the arms and legs, usually on both sides.
How is CIDP different from Guillain-Barre syndrome?
Both involve immune damage to nerve myelin, but Guillain-Barre syndrome comes on rapidly over days to weeks, while CIDP develops slowly over at least two months or follows a relapsing course. CIDP also usually lacks a clear preceding infection.
Is CIDP treatable?
Yes. CIDP is one of the more treatable nerve disorders. Treatments such as corticosteroids, intravenous immunoglobulin, and plasma exchange can reduce the immune attack and improve strength. Many people respond well, though long-term treatment is often needed.
Can CIDP be cured?
There is no permanent cure, but the condition can often be well controlled with treatment, and some people achieve long periods of remission. Early diagnosis and treatment improve the chances of recovery and help prevent lasting nerve damage.
What happens if CIDP is not treated?
Without treatment, CIDP can cause progressive weakness and numbness that lead to lasting disability and difficulty walking or using the hands. Because early treatment preserves nerve function, prompt evaluation of unexplained progressive weakness is important.
References
- National Institute of Neurological Disorders and Stroke (NINDS). Chronic Inflammatory Demyelinating Polyneuropathy.
- GBS/CIDP Foundation International. About CIDP.
- MedlinePlus, U.S. National Library of Medicine. Chronic inflammatory polyneuropathy.
- National Library of Medicine. StatPearls: Chronic Inflammatory Demyelinating Polyneuropathy.